Weight Loss Drugs Linked to Hair Loss

Key Takeaways

GLP-1 drugs were associated with an increased risk of hair loss.
Genetic data showed a modest alopecia risk in susceptible men.
GLP-1 users had higher alopecia rates than some diabetes-drug users.
Researchers are yet to determine why hair shedding occurs.

The most noticeable change after starting weight loss drugs (GLP-1 drugs) as may not always be the one people expect. For some people, it may be more hair collecting in the shower drain or left behind on a pillow. Its raises a simple question: is the medication responsible? That question is becoming increasingly relevant as GLP-1 drugs are used by more people, and two 2026 studies have now examined the possible connection with hair loss from very different perspectives. Their findings point to an association with alopecia, while leaving one important question unanswered: whether the medications themselves are responsible.

What are GLP-1 drugs, and why are so many people using them?

GLP-1 drugs are prescription medicines that act on receptors for glucagon-like peptide-1, a hormone involved in blood glucose regulation and appetite. The class includes medicines such as semaglutide and tirzepatide. Different GLP-1 drugs have different approved uses. Doctors prescribe GLP-1 drugs for conditions including Type-2 diabetes and, for certain medicines, chronic weight management. Their use has increased as these medicines have become more widely prescribed for diabetes and weight management. KFF reported in 2026 that 18% of US adults had used a GLP-1 medication at some point, while 12% said they were currently using one. Among adults who reported having diabetes, 45% said they were currently taking a GLP-1 drug.

GLP-1 drugs are not used only for weight loss. In a 2025 KFF survey, 38% of people who had used a GLP-1 drug said they used it primarily to treat a chronic condition. Another 32% used it for both a chronic condition and weight loss, while 30% said weight loss was their primary reason for use. With more people taking these medicines, researchers are examining possible effects beyond blood glucose and body weight. Hair loss is one of the questions being studied.

Questions about GLP-1 drugs extend beyond weight loss. Previous research has also examined their possible links to other health outcomes, including mental health and pregnancy. In an earlier report, we explored research on diabetes drugs (including GLP-1 drugs) and depression risk, while another looked at what a large study found about GLP-1 drugs and preterm birth risk during pregnancy. Together, these findings highlight why researchers continue to examine how these widely used medicines may affect different aspects of health.

What do new studies show about GLP-1 drugs and hair loss?

Two 2026 studies found associations between GLP-1-related factors and alopecia, but neither study established that GLP-1 drugs directly cause hair loss. The first study, from NYU Langone Health, used genetic data rather than medication records. Researchers examined the GLP1R gene, which encodes the receptor targeted by GLP-1 drugs. They compared genetic indicators associated with higher GLP-1 receptor activity with genetic information linked to androgenetic alopecia, a common form of patterned hair loss.

The analysis focused on men because male androgenetic alopecia is better characterized in the available genetic data. Among men who were already genetically susceptible to androgenetic alopecia, genetic indicators associated with higher GLP-1 receptor activity were linked to a 7% additional risk. The association remained after researchers accounted for hypertension. It also remained after they considered insulin resistance and lower testosterone. The 7% figure does not mean that taking a GLP-1 drug increases a person’s risk of hair loss by 7%. The study examined genetic associations, not medication use. It therefore cannot show that a GLP-1 drug caused the hair loss.

The second study, published in the BMJ, used electronic health records from Penn Medicine. Researchers compared people with type 2 diabetes who started GLP-1 receptor agonists with people who started SGLT-2 or DPP-4 inhibitors. GLP-1 receptor agonist use was associated with a higher risk of alopecia. Compared with SGLT-2 inhibitors, the hazard ratio was 1.37, with incidence rates of 6.91 versus 5.04 cases per 1,000 person-years. Compared with DPP-4 inhibitors, the hazard ratio was 1.68, with incidence rates of 6.53 versus 3.89 cases per 1,000 person-years. The study also found an association with non-scarring alopecia. The researchers could not determine the severity, duration or reversibility of the hair loss from the available medical records. Because the study was observational, the results show an association rather than a cause-and-effect relationship.

Why might GLP-1 drugs be linked to hair shedding?

The studies did not identify a specific biological mechanism connecting GLP-1 drugs with hair loss. One possible explanation involves changes that occur during substantial weight loss. Rapid weight loss and reduced calorie intake can affect the hair-growth cycle. The BMJ researchers noted that nutritional changes, including possible iron or zinc deficiencies, could contribute to telogen effluvium. Telogen effluvium is a form of hair shedding in which more hairs than usual enter the resting phase of the hair cycle.

Hormonal changes may also be relevant, but the available studies do not show that hormonal changes caused the observed hair loss. The current evidence therefore does not establish why the association occurs. Possible explanations include GLP-1 receptor activity, changes associated with weight loss, nutritional factors or other factors that were not measured in the studies. More research is needed to determine which explanation, if any, accounts for the findings.

FAQs on Weight Loss Drugs Linked to Hair Loss

Q: Are weight loss drugs linked to hair loss?
A: Current research suggests an association between GLP-1 drugs or GLP-1-related factors and alopecia, but it does not prove that the medications directly cause hair loss. A 2026 BMJ study found higher rates of alopecia among GLP-1 receptor agonist users, while a separate NYU study found a genetic association involving GLP-1 receptor activity and androgenetic alopecia.

Q: Can GLP-1 drugs like Ozempic and Wegovy cause hair loss?
A: Research has not established that Ozempic, Wegovy, or other GLP-1 drugs directly cause hair loss. One possible explanation is that rapid weight loss or reduced calorie intake can affect the hair-growth cycle and contribute to temporary shedding such as telogen effluvium.

Q: Why does hair fall out after taking weight loss medication?
A: Hair shedding may be associated with physiological changes that occur during substantial weight loss. Reduced calorie intake and possible nutritional deficiencies involving nutrients such as iron or zinc may affect the hair-growth cycle, although the studies discussed do not establish a single cause.

Q: What type of hair loss is associated with GLP-1 receptor agonists?
A: The 2026 BMJ study found an association between GLP-1 receptor agonist use and alopecia, including non-scarring alopecia. The NYU study specifically examined androgenetic alopecia, which is a common form of patterned hair loss, but the genetic study did not examine whether patients were taking GLP-1 medications.

Q: Is hair loss from GLP-1 drugs permanent?
A: The available BMJ study could not determine whether the hair loss associated with GLP-1 receptor agonist use was temporary or permanent. The researchers did not have enough information about the severity, duration, or reversibility of alopecia in the medical records.

Q: Is hair loss more common with GLP-1 drugs than other diabetes medications?
A: In the 2026 BMJ study, GLP-1 receptor agonist users had higher rates of alopecia than people who started SGLT-2 or DPP-4 inhibitors. The hazard ratio was 1.37 compared with SGLT-2 inhibitors and 1.68 compared with DPP-4 inhibitors, but the observational study cannot establish that GLP-1 treatment itself caused the difference.

Q: Who is more likely to experience hair loss with GLP-1 drugs?
A: The current research does not identify a specific group that is definitely more likely to experience medication-related hair loss. The NYU study found a genetic association among men who were already susceptible to androgenetic alopecia, but more research is needed to determine whether similar associations occur in women and other populations.

Q: How common is GLP-1 drug use in the United States?
A: KFF reported in 2026 that 18% of US adults had used a GLP-1 medication at some point and 12% were currently using one. Among adults who reported having diabetes, 45% said they were currently taking a GLP-1 drug, showing how widely these medicines are now used for chronic health conditions and weight management.

Q: What is telogen effluvium, and can weight loss trigger it?
A: Telogen effluvium is a form of hair shedding in which more hairs than usual enter the resting phase of the hair-growth cycle. Rapid weight loss and reduced calorie intake can affect this cycle, and the BMJ researchers identified nutritional changes as one possible explanation for hair shedding among GLP-1 users.

References

Disclaimer:
Some aspects of the webpage preparation workflow may be informed or enhanced through the use of artificial intelligence technologies. While every effort is made to ensure accuracy and clarity, readers are encouraged to consult primary sources for verification. External links are provided for convenience, and Honores does not endorse, control, or assume responsibility for their content or for any outcomes resulting from their use. The author declares no conflicts of interest in relation to the external links included. Neither the author nor the website has received any financial support, sponsorship, or external funding. This content is for informational purposes only and is not medical advice. Please consult a qualified physician before making health decisions. Images are for representational purposes only. Photo by Towfiqu barbhuiya from Pexels.